Fifth Third Bancorp
CRNX

Fifth Third Bancorp’s Crinetics Pharmaceuticals CRNX Stock Holding History

Fifth Third Bancorp’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Sell
3,421
-49
-1% -$1.82K ﹤0.01% 2840
2026
Q1 		$126K Buy
+3,470
New +$155K ﹤0.01% 2792

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fifth Third Bancorp's CRNX Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Crinetics Pharmaceuticals (CRNX) stake by 1.4% in Q2 2026, selling an estimated $1.82K and leaving 3,421 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

Fifth Third Bancorp first reported a position in CRNX in Q1 2026 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Fifth Third Bancorp held 3,421 shares of Crinetics Pharmaceuticals worth $128K as of Q2 2026.
  • Fifth Third Bancorp sold 49 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.82K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #2840 holding.
  • Fifth Third Bancorp first reported a position in Crinetics Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.